Our findings suggest that while PDE5 inhibition may be associated with a lower risk of vascular dementia, possibly by preventing white matter hyperintensities, it may increase risk of Alzheimer’s disease and Lewy body dementia, warranting further investigation before clinical trials. This evidence concerns the gene PDE5A and Lewy body dementia.